13.97 USD
-0.17 (-1.2%)
13.97 USD
0 (0%)
Overall AMRN gets a fundamental rating of 3 out of 10. We evaluated AMRN against 529 industry peers in the Biotechnology industry. The financial health of AMRN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, AMRN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
AMRN had negative earnings in the past year.
In the past year AMRN has reported a negative cash flow from operations.
In the past 5 years AMRN reported 4 times negative net income.
In the past 5 years AMRN reported 4 times negative operating cash flow.
1.2 Ratios
AMRN has a Return On Assets of -13.12%. This is amongst the best in the industry. AMRN outperforms 81.66% of its industry peers.
With an excellent Return On Equity value of -18.87%, AMRN belongs to the best of the industry, outperforming 83.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.12% | ||
| ROE | -18.87% | ||
| ROIC | N/A |
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AMRN has a better Gross Margin (54.96%) than 76.94% of its industry peers.
AMRN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AMRN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
2. Health
2.1 Basic Checks
AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMRN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AMRN has been increased compared to 5 years ago.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.73, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
AMRN has a Altman-Z score (-1.73) which is in line with its industry peers.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.73 |
ROIC/WACCN/A
WACC7.51%
2.3 Liquidity
AMRN has a Current Ratio of 3.45. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN has a Current ratio of 3.45. This is comparable to the rest of the industry: AMRN outperforms 40.45% of its industry peers.
AMRN has a Quick Ratio of 2.43. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.43, AMRN is not doing good in the industry: 70.13% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.45 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.56%, which is quite impressive.
AMRN shows a decrease in Revenue. In the last year, the revenue decreased by -5.93%.
Measured over the past years, AMRN shows a very negative growth in Revenue. The Revenue has been decreasing by -11.86% on average per year.
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
Revenue 1Y (TTM)-5.93%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%17.43%
3.2 Future
AMRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.76% yearly.
The Revenue is expected to grow by 26.83% on average over the next years. This is a very strong growth
EPS Next Y56.42%
EPS Next 2Y44.5%
EPS Next 3Y24.81%
EPS Next 5Y17.76%
Revenue Next Year10.03%
Revenue Next 2Y-0.3%
Revenue Next 3Y-0.52%
Revenue Next 5Y26.83%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 72.08, which means the current valuation is very expensive for AMRN.
Based on the Price/Forward Earnings ratio, AMRN is valued cheaply inside the industry as 89.41% of the companies are valued more expensively.
AMRN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 72.08 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AMRN's earnings are expected to grow with 24.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.5%
EPS Next 3Y24.81%
5. Dividend
5.1 Amount
No dividends for AMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
13.97
-0.17 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners20.09%
Inst Owner Change-4.09%
Ins Owners0.81%
Ins Owner Change0.54%
Market Cap290.47M
Revenue(TTM)226.73M
Net Income(TTM)-86.57M
Analysts42.86
Price Target12.24 (-12.38%)
Short Float %40.43%
Short Ratio3.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)290.01%
Min EPS beat(2)113.76%
Max EPS beat(2)466.25%
EPS beat(4)3
Avg EPS beat(4)148.54%
Min EPS beat(4)-30.72%
Max EPS beat(4)466.25%
EPS beat(8)6
Avg EPS beat(8)97.31%
EPS beat(12)7
Avg EPS beat(12)68.9%
EPS beat(16)9
Avg EPS beat(16)50.01%
Revenue beat(2)2
Avg Revenue beat(2)22.82%
Min Revenue beat(2)12.99%
Max Revenue beat(2)32.65%
Revenue beat(4)3
Avg Revenue beat(4)24.22%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.46%
Revenue beat(12)9
Avg Revenue beat(12)12.72%
Revenue beat(16)10
Avg Revenue beat(16)8.28%
PT rev (1m)12.5%
PT rev (3m)9.09%
EPS NQ rev (1m)134.38%
EPS NQ rev (3m)114.29%
EPS NY rev (1m)56.28%
EPS NY rev (3m)61.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)32.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 72.08 | ||
| P/S | 1.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.63 | ||
| P/tB | 0.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.62
EYN/A
EPS(NY)0.19
Fwd EY1.39%
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS10.9
BVpS22.07
TBVpS21.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.12% | ||
| ROE | -18.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.96% | ||
| FCFM | N/A |
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score4
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.45 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z | -1.73 |
F-Score4
WACC7.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
EPS Next Y56.42%
EPS Next 2Y44.5%
EPS Next 3Y24.81%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-5.93%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%17.43%
Revenue Next Year10.03%
Revenue Next 2Y-0.3%
Revenue Next 3Y-0.52%
Revenue Next 5Y26.83%
EBIT growth 1Y34.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.11%
EBIT Next 3Y20.89%
EBIT Next 5YN/A
FCF growth 1Y-354.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-337.33%
OCF growth 3YN/A
OCF growth 5YN/A
AMARIN CORP PLC -ADR / AMRN FAQ
What is the fundamental rating for AMRN stock?
ChartMill assigns a fundamental rating of 3 / 10 to AMRN.
What is the valuation status of AMARIN CORP PLC -ADR (AMRN) stock?
ChartMill assigns a valuation rating of 2 / 10 to AMARIN CORP PLC -ADR (AMRN). This can be considered as Overvalued.
Can you provide the profitability details for AMARIN CORP PLC -ADR?
AMARIN CORP PLC -ADR (AMRN) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for AMRN stock?
The Earnings per Share (EPS) of AMARIN CORP PLC -ADR (AMRN) is expected to grow by 56.42% in the next year.